BACKGROUND: Few new treatments have been developed for kidney failure or CKD in recent years, leading to perceptions of slower improvement in outcomes associated with CKD or kidney failure than for other major noncommunicable diseases. METHODS: Our retrospective cohort study included 548,609 people with an incident noncommunicable disease, including cardiovascular diseases, diabetes, various cancers, and severe CKD or kidney failure treated with renal replacement (KF-RRT), treated in Alberta, Canada, 2004-2015. For each disease, we assessed presence or absence of 8 comorbidities; we also compared secular trends in relative (compared to a referent year of 2004) and absolute risks of mortality and mean annual days in the hospital associated with each disease after 1 year and 5 years. RESULTS: Comorbidities increased significantly in number over time for all noncommunicable diseases except diabetes, and increased most rapidly for CKD and KF-RRT. Significant but relatively small reductions over time in the risk ratio of mortality at 1 year occurred for nearly all noncommunicable diseases. Secular trends in the absolute risk of mortality were similar; CKD and KF-RRT had a relatively favorable ranking at 1 year. Breast cancer, KF-RRT, diabetes, and colorectal cancer displayed the largest relative reductions in number of hospital days at 1 year. Significant absolute reductions in the number of hospital days were observed for both KF-RRT and CKD; the former had the highest absolute reduction among all noncommunicable diseases. Results were similar at 5 years. CONCLUSIONS: We observed secular reductions in mortality and annual hospital days at 1 year and 5 years among incident patients with KF-RRT and severe CKD, as well as several other common noncommunicable diseases.
BACKGROUND: Few new treatments have been developed for kidney failure or CKD in recent years, leading to perceptions of slower improvement in outcomes associated with CKD or kidney failure than for other major noncommunicable diseases. METHODS: Our retrospective cohort study included 548,609 people with an incident noncommunicable disease, including cardiovascular diseases, diabetes, various cancers, and severe CKD or kidney failure treated with renal replacement (KF-RRT), treated in Alberta, Canada, 2004-2015. For each disease, we assessed presence or absence of 8 comorbidities; we also compared secular trends in relative (compared to a referent year of 2004) and absolute risks of mortality and mean annual days in the hospital associated with each disease after 1 year and 5 years. RESULTS: Comorbidities increased significantly in number over time for all noncommunicable diseases except diabetes, and increased most rapidly for CKD and KF-RRT. Significant but relatively small reductions over time in the risk ratio of mortality at 1 year occurred for nearly all noncommunicable diseases. Secular trends in the absolute risk of mortality were similar; CKD and KF-RRT had a relatively favorable ranking at 1 year. Breast cancer, KF-RRT, diabetes, and colorectal cancer displayed the largest relative reductions in number of hospital days at 1 year. Significant absolute reductions in the number of hospital days were observed for both KF-RRT and CKD; the former had the highest absolute reduction among all noncommunicable diseases. Results were similar at 5 years. CONCLUSIONS: We observed secular reductions in mortality and annual hospital days at 1 year and 5 years among incident patients with KF-RRT and severe CKD, as well as several other common noncommunicable diseases.
Authors: Adeera Levin; Brenda Hemmelgarn; Bruce Culleton; Sheldon Tobe; Philip McFarlane; Marcel Ruzicka; Kevin Burns; Braden Manns; Colin White; Francoise Madore; Louise Moist; Scott Klarenbach; Brendan Barrett; Robert Foley; Kailash Jindal; Peter Senior; Neesh Pannu; Sabin Shurraw; Ayub Akbari; Adam Cohn; Martina Reslerova; Vinay Deved; David Mendelssohn; Gihad Nesrallah; Joanne Kappel; Marcello Tonelli Journal: CMAJ Date: 2008-11-18 Impact factor: 8.262
Authors: Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani Journal: Circulation Date: 2019-03-05 Impact factor: 29.690
Authors: Marcello Tonelli; Natasha Wiebe; Sharon Straus; Martin Fortin; Bruce Guthrie; Matthew T James; Scott W Klarenbach; Helen Tam-Tham; Richard Lewanczuk; Braden J Manns; Hude Quan; Paul E Ronksley; Peter Sargious; Brenda Hemmelgarn Journal: CMAJ Open Date: 2017-08-14
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: R Todd Alexander; Brenda R Hemmelgarn; Natasha Wiebe; Aminu Bello; Catherine Morgan; Susan Samuel; Scott W Klarenbach; Gary C Curhan; Marcello Tonelli Journal: BMJ Date: 2012-08-29
Authors: Marcello Tonelli; Natasha Wiebe; Martin Fortin; Bruce Guthrie; Brenda R Hemmelgarn; Matthew T James; Scott W Klarenbach; Richard Lewanczuk; Braden J Manns; Paul Ronksley; Peter Sargious; Sharon Straus; Hude Quan Journal: BMC Med Inform Decis Mak Date: 2015-04-17 Impact factor: 2.796
Authors: Brenda R Hemmelgarn; Fiona Clement; Braden J Manns; Scott Klarenbach; Matthew T James; Pietro Ravani; Neesh Pannu; Sofia B Ahmed; Jennifer MacRae; Nairne Scott-Douglas; Kailash Jindal; Robert Quinn; Bruce F Culleton; Natasha Wiebe; Richard Krause; Laurel Thorlacius; Marcello Tonelli Journal: BMC Nephrol Date: 2009-10-19 Impact factor: 2.388